Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
197 studies found for:    ABL1
Show Display Options
Rank Status Study
1 Recruiting Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Drug: Pioglitazone Hydrochloride;   Drug: Tyrosine Kinase Inhibitor (TKI)
2 Not yet recruiting Pre-existing Kinase Domain Mutations in Ph-positive Leukemias
Condition: Mutations in BCR-ABL Stem Cells
Intervention:
3 Recruiting Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Condition: Malignant Neoplasm
Interventions: Drug: ponatinib hydrochloride;   Other: laboratory biomarker analysis
4 Active, not recruiting Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib followed by treatment-free
5 Completed Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: nilotinib;   Drug: imatinib mesylate;   Other: pharmacological study
6 Completed Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase
Condition: Chronic Myeloid Leukemia in Chronic Phase
Intervention: Drug: LBH589
7 Completed Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
Condition: Leukemia, Myeloid, Chronic
Intervention: Drug: panobinostat
8 Terminated Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy
Condition: Myeloid Leukemia, Chronic
Intervention: Drug: Nilotinib 300 mg.
9 Active, not recruiting Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
Conditions: Leukemia;   Leukemia, Myeloid;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Philadelphia Chromosome;   Hematologic Diseases
Intervention: Drug: Radotinib
10 Active, not recruiting
Has Results
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase of Disease
Interventions: Drug: Dasatinib;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis
11 Completed Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia
Interventions: Drug: omacetaxine mepesuccinate;   Drug: cytarabine;   Other: laboratory biomarker analysis
12 Recruiting Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Neutrophilic Leukemia
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: Ruxolitinib Phosphate
13 Terminated Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
Conditions: Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Biological: bevacizumab;   Drug: idarubicin;   Drug: cytarabine
14 Active, not recruiting Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: Alemtuzumab;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide Phosphate;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Melphalan;   Drug: Mercaptopurine;   Drug: Methotrexate;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: Tacrolimus;   Drug: Vincristine Sulfate
15 Active, not recruiting Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: imatinib mesylate;   Drug: dasatinib;   Drug: nilotinib;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation;   Biological: therapeutic allogeneic lymphocytes
16 Active, not recruiting Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Behavioral: Interruption of the treatment by Imatinib
17 Recruiting Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)
Condition: Leukemia, Myeloid, Chronic-Phase
Intervention: Drug: Pioglitazone
18 Unknown  Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission
Conditions: Chronic Myelogenous Leukemia;   Short Stature
Intervention: Drug: Growth Hormone
19 Completed OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)
Condition: Chronic Myelogenous Leukemia, BCR/ABL Positive
Intervention: Drug: Dasatinib
20 Recruiting A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
Conditions: Colorectal Cancer;   Head and Neck Cancer
Intervention: Drug: Nilotinib + Cetuximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.